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ABSTRACT 
Identification of Pks13 Inhibitors for Antitubercular Drug Discovery 
 
Stephanie Leon Quinonez 
Department of Chemistry 
Texas A&M University 
 
Research Advisor: Dr. James Sacchettini 
Department of Biochemistry 
Texas A&M University 
 
 
Frontline tuberculosis drugs, i.e. Isoniazid, have become inefficient as strains of 
Mycobacterium Tuberculosis have become multi-drug resistant, creating an urgent need for 
novel antitubercular drugs. The key to the bacterium resistance lies within its thick and complex 
cell wall, where mycolic acids (MAs) are the major constituents and contribute to the 
permeability of the cell wall and the resistance of the organism. The last step in their biosynthetic 
formation is done by polyketide synthase 13, which produces the α-alkyl-β-ketoester precursors 
leading to MAs formation. We have identified a compound in previous studies, IMTB-28,  able 
to bind to the Pks13 Thioesterase domain, a domain where no major research has been done 
before. Inhibition of Pks13 TE domain by IMTB-28 prompt structural changes in Pks13 that 
make it unable to function properly and stop product formation. This research identified a 
compound, TAMU196,  within a series of IMTB-28 analogs, with great potency against the 
Pks13 TE domain and Mtb cells, and low toxicity against human cells. Eight commercially 
available compounds were also identified having 100% inhibition against the Pks13 TE domain 
at 10 µM concentration. These inhibitors can be used as scaffolds for structural changes in the 
path to becoming the next antitubercular drug and save the lives of patients with multi-drug 
resistant tuberculosis worldwide.  
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NOMENCLATURE  
 
Mtb  Mycobacterium Tuberculosis 
TB  Tuberculosis 
MAs  Mycolic Acids 
Pks13   Polyketide Synthase 13  
TE  Thioesterase 
HDF  Human Dermal Fibroblast 
IC50  Half Inhibitory Concentration 
MIC50   Half Minimal Inhibitory Concentration 
O.D  Optical Density 
RFU   Relative Fluorescence Units  
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CHAPTER I 
INTRODUCTION 
 
The Need for Novel Antitubercular Drugs 
Tuberculosis (TB) remains today as one of the deadliest diseases as strains of 
Mycobacterium Tuberculosis (Mtb), the causative agent of tuberculosis, have developed 
resistance to commonly used TB antibiotics, i.e.,  Isoniazid and Rifampicin [1]. Only in the year 
2014, TB infected around 9.6 million people, killing 1.5 million [2]. This has placed an urgent 
need in the development of novel TB compounds. 
The success of Mtb as a pathogen lies within its thick and complex cell wall, which is the 
key factor in its physiological and pathogenic aspects, and its antibiotic resistance and 
susceptibility [3]. Its main constituents, mycolic acids (MAs), are α-branched and β-
hydroxylated long chain fatty acids that help Mtb increase resistance against chemical damage, 
hydration, and hydrophobic antibiotics. The MAs essentiality for the survival of Mtb, and having 
their biosynthetic pathway inhibited by the most efficient anti-TB drug Isoniazid as an effect [4], 
makes the MAs pathway a crucial source for effective target identification for novel anti-TB 
drugs. 
Pks13 TE Domain Drug Discovery 
Within the Corynebacterineae suborder, MAs have a common 2-alkyl 3-hydroxyl 
segment, found to be biosynthesized by precursors formed by polyketide synthase 13 (Pks13). 
This enzyme contains an acyl transferase domain, a ketosynthase domain, an acyl carrier protein 
domain, and a thioesterase domain (TE); and catalyzes the last step in the MAs biosynthetic 
pathway by synthesizing the α-alkyl-β-ketoester precursors that form the mentioned MA segment 
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[3]. Inhibition of Pks13 would lead to a discontinuation in the formation of MAs, which would 
result in the disruption of the bacterial cell wall and elimination of Mtb. In previous studies, we 
have identified a lead benzofuran compound, IMTB-28 (See Figure 1), that inhibits the Pks13 TE 
domain by blocking the release of the MA precursors by de-esterification. We have solved the 
inhibitor structure in complex with the TE domain, and we have used this information to 
synthesize IMTB-28 analogs containing the benzofuran core and differing R groups[5].   
 
Figure 1. IMTB-28 binding to Pks13 Thioesterase Domain. The picture taken from previous studies, and depicts the binding 
site of the IMTB-28 lead molecule, containing a benzofuran core.  
This research strives to identify potent IMTB-28 analogs through the use of  in vitro 
studies to assess the inhibitory potency of these compounds against Pks13 TE domain, their 
killing activity against Mtb cells, and their cytotoxicity activity against human dermal fibroblast 
cells. This research will also strive to find active inhibitors, or hits, of the Pks13 TE domain 
using high throughput screening. Inhibition of Pks13 TE domain by these inhibitors will prompt 
structural changes in Pks13 that will make it unable to function properly and stop MAs 
formation. Success will result identifying potent and active Pks13 able to be used as scaffolds for 
further investigation in the path for developing a drug able to combat resistant strains of TB and 
save millions of lives.  
 6 
 
CHAPTER II 
MATERIALS AND METHODS 
 
 
In Vitro Assays 
Absolute IC50 of Compounds Against Pks13 
Assay 
Compound dilutions were first made in a 2-fold series ( 10 µM- 0.00098 µM) using 
dimethyl sulfoxide (DMSO, Sigma Aldriech) as solvent in a 96-well plate (VWR). The 100 µL 
assay was then performed using Tris buffer (0.25M, pH 7.0) , purified Pks13 TE domain ( 100 
nM), 1 µL compound dilutions from the dilution plates, and 4-Methylumbelliferyl heptanoate 
(MUH, 20mM, Sigma-Aldrich). The constituents of the assay were added and mixed in this 
exact sequence. The assay mapping was divided into  positive controls ( Pks13 TE + MUH+ 
Compound) from rows A-D and columns 1-11, a negative control ( MUH + Compound) from 
rows E-H and columns 1-11, and a DMSO control from column 12, were used for data analysis.  
The plate was then red with a microplate reader ( Omega FLUOstar) at 560 nm.  The %inhibition 
was calculated and  plotted against log(concentration) using Prism (GraphPad Software) to 
determine IC50 values.  
Absolute MIC of Compounds in Wild Type Mtb27000 Cells 
Cell Culture  
The Mc27000 Mtb cell line was commercially available. The culture was made with 10 
mL 7H9 Broth using OACD (1x), Tyloxapol (50%), Pantothenic acid (50 mg/mL), Malachite 
green (0.25 mg/mL), and 1 mL of P1 Mtb cells ( 0.01 O.D). This was incubated at 370 C for 7 
days. 
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Single and Multiple Carbon Source Assay 
Three-fold dilutions plates were made with a [0.5 mM]0 . Using the cell culture at an O.D 
of 0.8 at 560 nm, cells were prepared with 2 different carbon sources in 2 different media for a 
final O.D of 0.01 at 560 nm: one 20 mL Dextrose 7H9 Broth prep-media with a final 
concentration of Dextrose (0.5 %), NaCl (0.085 %), Tyloxapol (0.25 ug/mL), Pantothenic Acid 
(50 mg/mL), and Malachite Green (0.25 mg/mL), in the assay plate; and one 20 mL Dextrose + 
Acetate M9 prep-media with a final concentration of Sodium Acetate (0.25%), Dextrose (0.25 
%), Magnesium Sulfate (2 nM), Calcium Chloride (125 µM), Malachite Green (0.25 mg/ mL), 
Tyloxapol ( 0.05%), Pantothenic Acid (50 mg/mL), in the assay plate. Using the dilution plate, 4 
µL of compound from Row A was transferred to Row A in 2 assay plates, Row B to Row B in 
both assay plates, respectively. A portion of 196 µL of M9 prep-media and 7H9 prep-media was 
added into their respective assay plates, giving a total assay volume of 200 µL. For rows A-H, 
from column 2-11, the final concentrations of the compound in the assay plate ranged from 10 
µM- 0.00050805 µM in a 3-fold series. Undiluted Rifampicin (10 uM) was used in column 12 as 
positive control, DMSO was used in column 1 as negative control, the wells at the edge in row H 
were used as cell-only control, and row H was used as the diluted Rifampicin control. The plates 
were incubated at 370 C for 7 days, then stained with Resazurin (0.25 mg/mL) for 2 days, and 
finally red with a microplate reader (Omega FLUOstar) with a fluorescence protocol at 560 nm. 
The data was analyzed through a %growth calculation and a dose-response was determined by 
plotting the %inhibition against the log(concentration) of the compound using GraphPad Prism ( 
Graphpad Software) to determine the MIC50 value.   
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Absolute MIC50 of Select Compounds in IMTB-28 Resistant mutant Mtb Mc
27000 Cells 
Cell Culture and Assay 
Resistant cells were obtained from previous studies. The cell culture and assays were 
performed using the procedure for wild type but with resistant mutant cells. The plates were 
stained with Resazurin after 5 days, and red with a fluorescence protocol after 2 days.  
Human Dermal Fibroblast Cytotoxicity Assay 
Human dermal fibroblasts (HDF) cells were purchased from ATCC (Manassas, VA).   
HDF cells were cultured in DMEM (Lonza) media supplemented with 10% fetal bovine serum 
(Lonza) and penicillin/streptomycin (Lonza).  For the cytotoxicity assay, compound stocks were 
serially diluted in phosphate buffered saline (PBS) plus 10% DMSO.  On the day of assay, HDF 
cells were trypsinized, counted and resuspended at a concentration of 64,000 cells/ml in media.  
Cells were plated, overlaid with the compound serial dilutions and incubated at 37C.  After 48h, 
Resazurin dye was added and the assay plates cultured for another 24h.  The next day the 
absorbance of the Resazurin was measured on a microplate reader to assess cell death.   
Cytotoxicity was determined as a percent of dead cells versus living.   
High Throughput Screening 
Assay 
A compound library consisting of three 384-well plates (VWR) with a total of 924 
compounds  were screened against Pks13 TE for a period of 2 hours at room temperature for hit 
identification. The assay was done with the aid of the CyBio automated system, with a 
formulated protocol for a 50 µL assay containing Tris buffer (0.25M, pH 7.0), the Pks13 TE 
domain ( 100 nM), compounds from the compound library plates ( 10µM), and MUH substrate 
(20 µM), all added and mixed in this exact sequence. A positive control (Pks13 TE domain + 
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MUH), a negative control (MUH only), and a reference control (Pks13 TE domain + a potent 
IMTB-28 analog) were used. Once the assay was completed, the plates were red in a 
fluorescence protocol using a microplate reader ( Omega  FlUOstar), and the enzyme activity 
was analyzed through calculating 1-%activity ( Pks13 + compound activity/ Pks13 activity). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10 
 
CHAPTER III 
RESULTS AND DISCUSSION 
 
Potent Pks13 Inhibitors in the IMTB-28 Analogs Series 
IC50 and MIC50 testing 
The first step to discover potent pks13 TE domain inhibitors in the IMTB-28 analog 
series was to assess their inhibitory activity based on IC50 and simultaneously validate the Pks13 
TE domain as their specific target. The same optimized assay conditions from previous 
laboratory work on Pks13 were used for this experiment, consisting of a final Pks13 TE domain 
concentration of 100 nM, and the use of MUH as a substitute substrate to mimic Pks13 TE 
domain substrate with a final concentration of 20 µM.  
Results were obtained by a construction of a dose-response graph and evaluation of the 
activity of the antagonist (the IMTB-28 analog) versus the activity of the agonist (MUH), and 
calculating the concentration of the antagonist needed to inhibit half of the biological response 
formed by the agonist [6]. A small IC50 value indicated greater inhibitory activity by the 
compound as a small concentration was needed to competitively inhibit Pks13 activity and 
prevent MUH binding leading to product formation.  
After validating Pks13 TE domain as their direct target, the most active compounds  (See 
Figure 2) were tested in an MIC50 experiment  against  Mtb Mc
27000 cells to determine their cell 
killing activity [7]. The results were obtained through a dose-response of the half minimal 
inhibitory concentration ( MIC50) of the compound needed to inhibit 50% of cell growth. This 
experiment  was done in single (dextrose) and multiple (dextrose + acetate) carbon source, the 
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latter being the one most reflective of compound activity inside our body,  to assess the effect of 
carbon source in compound activity.  
 
Figure 2. Summary results of selected potent IMTB-28 analogs series. Structure of IMTB-28 as the structure of the 
compounds are confidential and cannot be disclosed on the left, and a table of results which include IC50 values, and MIC50 
values w/ different amount of carbon sources on the right. 
Analogs w/ Spirocyclic Amines (TAMU185 & 196) 
In comparison to the other active analogs, both TAMU185 and 196 contained a 
spirocyclic amine as one of the P groups, and killed the cells in both single and multiple carbon 
source with an MIC50 less than 10 µM (See Figure 3). TAMU185, containing a secondary amine 
instead of an ester as TAMU196, showed greater activity against Pks13 and Mtb cells.  
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Figure 3 . Multiple carbon source dose-response graph of potent IMTB-28 analogs. (A)  Graph of TAMU185. The activity 
of the compound decreases as the dose-response shifts from an MIC50 of 0.029 to 1.24 µM. (B) Graph of TAMU196. This 
compounds has a smother and more sigmoidal shape graph than TAMU185, and its activity decreases from 0.078 to 2.159 µM, 
having a larger shift decrease than TAMU185. 
In the dose-response graph, a shift in the sigmoidal curve was seen in the multiple carbon 
source experiment leading to a higher MIC50 value and lower compound activity against the Mtb 
cell. A possible reason was that because the Mtb cells have access to not just one, but two carbon 
sources, more cells were reproduced and more compound was required to kill 50% of the cell 
population resulting in a greater MIC50. This possibility, however, fails to explain why other 
IMTB-28 compounds do not show activity against Mtb cells in multiple carbon sources but do 
kill in single carbon source. TAMU190 and TAMU195 have only one P group different than 
TAMU185 and TAMU196, where in place of a spirocylic amine have a cyclic amine. This cyclic 
amine allows them to have more potency against the Pks13 TE domain, but makes them unable 
to kill cells in multiple carbon source MIC50. 
Analogs w/ Cyclic Amines (TAMU190 & 195) 
These benzofuran molecules contained a cyclic amine as one of the P groups; TAMU195 
contained an ester while TAMU190 contained a secondary amine. TAMU190 showed greater 
potency with a two-fold increase in both IC50 determination and MIC50 with dextrose-only 
carbon source. These analogs showed no MIC50 <10 µM in mixed carbon source. 
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Resistant Mutant MIC50 
Once established that these compounds were potent against Mtb cells, the next step was 
to do an experiment to verify the Mtb killing efficiency of the inhibitors due to specifically 
targeting the Pks13 TE domain within the Mtb cell. For this, an MIC50 assay was performed 
using grown IMTB-28 resistant mutant Mtb cells rather than wild type cells as in previous MIC50 
experiments,  and holding the remaining assay conditions from the previous MIC50 single carbon 
source assay constant. The results were also obtained through a dose response w/ % growth of 
the cells, and these MIC50 values were compared to the values obtained from the wild type single 
carbon source assay (See Figure 4). A positive outcome, where the Pks13 inhibitors fail to kill 
cells resistant to them, was determined by the resazurin dye reduction to resofurin resulting in an 
overall pink color.  
 
Figure 4.Compounds against resistant IMTB-28 Mtb Mc2700 cells MIC50 plate. Coloring of the wells after Rezasurin 
staining for two days. Both compounds show activity against cells resistant to their activity against Pks13 TE domain.  
Both TAMU185 and TAMU196  had a negative result of inhibiting the growth of cells 
that were resistant to their main benzofuran structure making them  IMTB-28 analogs. This 
meant that even though these compounds killed Mtb cells and inhibited the Pks13 TE domain 
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directly, there was no certainty  both compounds killed the cells because of inhibiting Pks13 and 
something else vital for cell survival, or inhibiting something else vital for cell survival and not 
Pks13 once inside the Mtb cell where they needed to look for the Pks13 target. However, both 
compounds remain potent inhibitors against Mtb and Pks13 TE domain, but further investigation 
will need to be done to verify the specific target of these compounds once inside the cell as they 
show potency against IMTB-28 resistant mutant Mtb cells (See Table 1).  
Table 1. MIC50 values of compounds against wild type and resistant mutant Mtb cells*.  
 
*Both compounds showed activity against the resistant mutant cells despite resistivity of the cells against them, with similar 
MIC50  values against wild type cells. This indicated the possibility of cell killing activity of the compounds due to binding to 
Pks13 and another target, or cell killing due to binding to a target other than Pks13 within the cell.  
 
 
HDF Cytotoxicity Testing 
After determining two compounds within the IMTB-28 series, TAMU185 and 
TAMU196,  to have great potency against the Pks13 TE domain and have killing proficiency 
against Mtb cells in a multiple carbon source environment, the consequent step was to verify if 
these compounds toxic to Mtb were also toxic to human cells and thus unable to be key 
compounds for tuberculosis drug discovery. A quick and simple method to test the cytotoxicity 
of these compounds against human cells was through an HDF cytotoxicity assay in collaboration 
with another laboratory member. This fibroblast-based assay uses human lung fibroblast cells 
sensitive to  mycobacterial cytotoxicity, and are able to respond to the viability of the bacilli in a 
dose-response behavior[8].  After obtaining the results, the percent cell viability of the cells was 
IMTB-28 Analog 
 
Wild Type Mtb Mc27000 
MIC50 (µM) 
IMTB-28 Resistant Mtb Mc27000 
MIC50 (µM) 
TAMU185 0.03 0.08 
TAMU196 0.07 0.05 
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calculated and  plotted against the log of the concentration of the compound to determine IC50. 
TAMU185 and TAMU196 gave an IC50 of 12.5 µM and >100 µM, respectively (See Figure 5). 
 
Figure 5. HDF assay results. TAMU196 shows no cytotoxic activity against human cells at MIC50 concentrations <100 µM. 
TAMU185 shows high cytotoxic activity.  
TAMU196 showed low toxic effects against human cells as more than 100 µM 
concentration is needed to kill 50% of the cells. TAMU185, however, showed high cytotoxicity 
with an IC50 of 12.5 µM, making TAMU196 a safer compound for in vivo testing and selection as 
a lead molecule for drug discovery.  
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Active Pks13 TE Inhibitors from a Compound Library 
High Throughput Screening 
 High Throughput Screening is used to test many molecules in a plate or a set of plates 
denominated a compound library, against the organism of interest, i.e. protein or cell, to find 
active inhibitors [9]. This experiment was done previously with a random compound population 
to determine the molecules within this population with the ability of inhibiting Mtb growth. The 
compounds with activity against Mtb were selected and saved for further characterization. In this 
experiment, a secondary assay was done using the selected population to determine which, if 
any, could inhibit the Pks13 TE domain specifically. Because the tested population was a biased 
one taken from the actual random population, percent inhibition, and not normal population 
statistics, were used as a method of identification.  
The assay consisted in having the same Pks13 TE domain and MUH concentration as in 
the IC50 assay, but without a range of compound concentration, for all the wells in the 384-well 
compound library plates, except for the ones left for the controls, contained a different compound 
each. Therefore, the only compound concentration tested against the Pks13 TE domain was at 10 
µM as a singlet. In contrast with the IC50 experiment, there was no dose-response of agonist vs 
antagonist as only one concentration was tested. Therefore, for data analysis, the controls were 
used with the sample data to produce 1-percent activity, i.e., percent inhibition. The percent 
activity was calculated using the relative fluorescence unit (RFU) values of the Pks13 TE-
compound complex divided by the RFU values of the Pks13 TE activity. Only 8 out of 924 
compounds, showed a fluorescence signal below the threshold of the sample mean [9], deviating 
a nσx from the sample x̅  (See Figure 6). This compounds also gave a 100% inhibition when 
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calculated, and thus with their location with respect to the sample mean and controls, and 
%Inhibition results, these were considered possible active compounds, or hits.  
 
Figure 6. Screening Results. Hits at 10 µM after 2 hrs of incubation with 100% inhibition. A-C are controls: A is the Pks13 TE 
domain with MUH positive control, B is the Pks13 TE domain with a potent IMTB-28 compound, and C is the MUH only 
negative control(A) Portrays the results in plate 1 where three possible active inhibitors (K22, N16, N23), or hits, were identified 
as they are below the sample mean along with the antagonist MUH-only. (B) shows E18, H18, and J2 and (C) shows only B5 and 
K14. Even though Normal populations statistics are used here to portray the character of these molecules, % inhibition was used 
for assessment instead of Z-factor as this population is not a random population, but a biased population taken from the random 
population.    
The structures of these compounds cannot be disclosed, but these are molecules with low 
MW, most have an amine as the central core with aromatics as R groups, with halogens such as 
Cl and S connected to these aromatics, with a structure similar to frontline TB drug Isoniazid, 
and are commercially available. However, even though these hits appear to be active against the 
Pks13 TE domain, an overall screening data contains plenty of variability [9] as these 
compounds were tested only as singlet at 10 µM. The screening results graphs, however, allowed 
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the visualization of compounds deviating from the sample mean and allowed pinpointing them 
for further dose-response IC50 analysis. Therefore, the assay was successful in identifying 
compounds appearing to be active against the Pks13 TE domain.  
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CHAPTER IV 
CONCLUSION 
 
From the IMTB-28 series, two compounds, TAMU185 and TAMU196, were found to be 
potent Pks13 TE inhibitors with IC50 values less than 1.5 µM. They were also found to be potent 
Mtb killing compounds with MIC50 in single and multiple carbon source , with values less than 
2.3 µM, although target specificity that allows for their killing activity within the Mtb cell needs 
to be further determined as they were also active against IMTB-28 resistant Mtb Mc27000 cells. 
TAMU196 proved to be a safer  potent inhibitor for antitubercular drug discovery as it is not 
cytotoxic against human cells in concentrations lower than 100 µM. Multiple commercially 
available hits were also found to be active against the Pks13 TE domain. Overall, this study 
successfully identified Pks13 TE domain inhibitors with 100% inhibition, and potent Pks13 TE 
domain inhibitors within the IMTB-28 analog series, which can be used as scaffolds for 
structural modification in the path to becoming a novel antitubercular drug. 
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